Status:

COMPLETED

Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making

Lead Sponsor:

Vigilant Biosciences, Inc.

Collaborating Sponsors:

Pearl Pathways

Conditions:

Palatal Neoplasms

Lip Neoplasm

Eligibility:

All Genders

23+ years

Brief Summary

Objectives Validate the OncAlert® RAPID Test by demonstrating that NPV \> (1 -prevalence). Evaluate the independent and associated contribution of readily available clinical variables including age, ...

Detailed Description

Overview The OncAlert Oral Cancer RAPID Test (OncAlert RAPID) is a qualitative point-of-care lateral flow assay to aid in the decision to biopsy in patients with clinical features associated with ora...

Eligibility Criteria

Inclusion

  • 23 years of age or older
  • A clinical suspicion of oral potentially malignant disorders, oral or oropharyngeal cancer, or both based in part on clinical examination, symptoms, clinical history, suspicious lesion(s) in mouth without history of a prior positive biopsy.
  • The subject must be able to comprehend and sign an approved Informed Consent Form and other applicable study documents.
  • Patients are eligible regardless of race, gender, and ethnicity

Exclusion

  • Prior history and/or diagnosis of any HN cancer/HNSCC of the oral cavity, oropharynx, or hypopharynx including nasopharyngeal carcinoma.
  • Prior treatment of HN cancer / HNSCC of the oral cavity, oropharynx, or hypopharynx including nasopharyngeal carcinoma.
  • Prior history of a positive biopsy of the oral cavity or oropharynx.
  • Planned excisional biopsy for a pathology diagnosis of HNSCC
  • Clinical presentation without localizing findings
  • Prior history of a salivary gland tumor
  • Current and or prior diagnosis of cancer (note: other than basal and squamous cell carcinoma of the skin) within the past 5 years.
  • Pregnant

Key Trial Info

Start Date :

September 7 2017

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 20 2020

Estimated Enrollment :

893 Patients enrolled

Trial Details

Trial ID

NCT03239834

Start Date

September 7 2017

End Date

December 20 2020

Last Update

August 12 2021

Active Locations (26)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (26 locations)

1

Dr. Joel Epstein

Beverly Hills, California, United States, 90211

2

Biosolutions Clinical Research Center

La Mesa, California, United States, 91941

3

Loma Linda School of Dentistry

Loma Linda, California, United States, 92350

4

Tower ENT, based at Cedars Sinai Medical Center

Los Angeles, California, United States, 90048